Panitumumab is indicated for the treatment of metastatic colorectal cancer that expresses epidermal growth factor receptor (EGFR) and has progressed following chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan; as a first-line therapy in combination with FOLFOX4 (fluoropyrimidine, leucovorin, and oxaliplatin) for metastatic colorectal cancer with wild-type KRAS; and as a second-line therapy in combination with FOLFIRI (fluoropyrimidine, leucovorin, and irinotecan) for wild-type KRAS metastatic colorectal cancer that has progressed after fluoropyrimidine-based chemotherapy.